News | May 22, 2022
Govt. launches single national portal for biotech researchers and start-ups
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
